Calcification and ossification of muscle

M13_CALCIOSSIMUSCLE

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — M61
  • Hospital discharge: ICD-9 — 7281B|7281X
  • Hospital discharge: excluded ICD-10 — M61.0, M61.1
  • Cause of death: ICD-10 — M61
  • Cause of death: ICD-9 — 7281B|7281X
  • Cause of death: excluded ICD-10 — M61.0, M61.1

2 out of 7 registries used, show all original rules.

96

4. Check minimum number of events

None

96

5. Include endpoints

None

96

6. Filter based on genotype QC (FinnGen only)

94

Control definitions (FinnGen only)

Control exclude
M13_SOFTTISSUE

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
M60-M63
Name in latin
Calcificatio et ossificatio musculi

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 594 264 323
Only index persons 508 233 275
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.01
Only index persons 0.01 0.01 0.01
Median age at first event (years)
Whole population 53.41 53.62 53.09
Only index persons 52.03 52.67 51.49

-FinnGen-

Key figures

All Female Male
Number of individuals 94 44 50
Unadjusted period prevalence (%) 0.02 0.02 0.02
Median age at first event (years) 53.60 48.76 57.87

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
96
Matched controls
960
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M61.9
ICD-10 Finland
Calcification and ossification of muscle, unspecified
+∞
41.7
37
*
M61.4
ICD-10 Finland
Other calcification of muscle
+∞
22.8
21
*
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
7.0
14.7
27
51
N03AX16
ATC
[U] pregabalin
5.2
13.4
38
107
M61.5
ICD-10 Finland
Other ossification of muscle
+∞
11.7
11
*
M61.3
ICD-10 Finland
Calcification and ossification of muscles associated with burns
+∞
10.6
10
*
M75.4
ICD-10 Finland
Impingement syndrome of shoulder
61.4
9.9
11
*
M61.2
ICD-10 Finland
Paralytic calcification and ossification of muscle
+∞
9.5
9
*
N02AX02
ATC
tramadol; systemic, rectal
3.7
9.4
55
253
M75.1
ICD-10 Finland
Rotator cuff syndrome
4.2
8.8
29
89
N06AX21
ATC
duloxetine; oral
5.8
8.8
18
37
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
3.5
8.5
47
205
M16.1
ICD-10 Finland
Other primary coxarthrosis
4.6
7.7
21
55
L13
ICPC
Hip symptom/complaint
3.6
6.8
27
93
T84.0
ICD-10 Finland
Mechanical complication of internal joint prosthesis
13.6
6.8
11
9
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
3.2
6.6
35
145
M79.6
ICD-10 Finland
Pain in limb
3.0
6.6
44
209
N02BF01
ATC
gabapentin; oral
4.7
6.4
16
39
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.3
6.3
30
116
7281X
ICD-9 Finland
Disorders of muscle, ligament and fascia, Muscular calcification and ossification[CALCIFICATIO ET OSSIFICATIO MUSCULI ALIA]
+∞
6.3
6
*
J01MA02
ATC
ciprofloxacin; systemic
2.9
6.2
47
237

TimeCodeWAS

↥

TimeCodeWAS is a tool for exploring time-dependent associations between an endpoint and health codes (diagnoses, lab tests, procedures, etc.).

The TimeCodeWAS analysis is done in three steps:

  1. Build a matched case-control set for this endpoint. Each case is matched to 5–10 controls on sex and year of birth, and controls must be at risk at the same age as the case's age of onset. TimeCodeWAS allows for controls to be reused.
  2. Count cases and controls. For each health code, and for each time window: tally the counts into a 2×2 table. To be eligible in a time window, a case or control must have data coverage for at least 50% of that time window.
  3. Perform association tests. If all cells of the 2×2 table have N≥10, then a χ² test is performed, otherwise a Fisher's exact test is done. The corresponding p-value and confidence interval are reported below, along with the standard odds ratio when a χ² test is done, or Fisher's MLE odds ratio otherwise.

TimeCodeWAS currently uses the same default set of time windows for all the endpoints. Please reach out to us if you have suggestions for better time windows for some endpoints. The default time windows are: TimeCodeWAS time windows

Sort & Filter
Sort
Odds Ratio
among windows:
Filter
Code & OMOP
Cases and controls with code
in
Odds Ratio
in
OMOP Concept
Code (OMOP Vocabulary) [OMOP Concept ID]
OMOP Concept Class / OMOP Domain
Odds Ratio
TimeCodeWAS O.R. time legend
Cases and controls with code
TimeCodeWAS Cases and Controls percentages time legend
Case Management Agency
251B00000X (NUCC) [38004193]
Visit / Visit
3.5e-02 1.0e-01 4.7e-01 4.0e+00 6.1e-01 -5.5e-03 7.2e-02
41.94%/41.08% 37.63%/35.27% 22.58%/15.38% 22.58%/0.54% 23.66%/14.42% 36.67%/36.80% 53.66%/51.86%
General Surgery
2 (Medicare Specialty) [38004447]
Physician Specialty / Provider
1.6e+00 2.0e+00 2.9e+00 1.0e+50 2.9e+00 2.0e+00 1.3e+00
45.16%/14.30% 25.81%/4.52% 10.75%/0.65% 37.63%/0.00% 11.83%/0.75% 27.78%/4.97% 41.46%/16.09%
Outpatient Hospital
22 (CMS Place of Service) [8756]
Visit / Visit
1.5e+00 1.6e+00 — 1.0e+50 2.8e+00 1.9e+00 1.1e+00
47.31%/17.31% 19.35%/4.73% —/— 17.20%/0.00% 9.68%/0.65% 20.00%/3.76% 39.02%/17.20%
Orthopedic Surgery
20 (Medicare Specialty) [38004465]
Physician Specialty / Provider
1.8e+00 2.5e+00 1.0e+50 1.0e+50 — 2.7e+00 2.0e+00
26.88%/5.59% 18.28%/1.83% 10.75%/0.00% 23.66%/0.00% —/— 25.56%/2.21% 37.80%/7.67%
Urgent procedure
ZXD05 (NCSPfi) [2001311386]
NCSPfi Level 3 / Procedure
1.2e+00 2.5e+00 — — — — —
6.45%/2.04% 6.45%/0.54% —/— —/— —/— —/— —/—
ipratropium bromide; inhalant
R03BB01 (ATC) [21603293]
ATC 5th / Drug
2.5e+00 — — — — — —
6.45%/0.54% —/— —/— —/— —/— —/— —/—
Neurology
13 (Medicare Specialty) [38004458]
Physician Specialty / Provider
7.2e-01 1.0e+00 2.5e+00 — — 1.0e+00 9.9e-01
11.83%/6.13% 8.60%/3.33% 6.45%/0.54% —/— —/— 7.78%/2.98% 19.51%/8.29%
Hand Surgery
40 (Medicare Specialty) [38004480]
Physician Specialty / Provider
2.5e+00 — — 1.0e+50 — — 2.0e+00
7.53%/0.65% —/— —/— 5.38%/0.00% —/— —/— 6.10%/0.87%
paracetamol; oral, parenteral, rectal
N02BE01 (ATC) [21604344]
ATC 5th / Drug
5.5e-01 7.0e-01 1.1e+00 — 2.5e+00 5.5e-01 8.9e-01
27.96%/18.28% 18.28%/10.00% 5.38%/1.83% —/— 7.53%/0.65% 16.67%/10.39% 40.24%/21.66%

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
22
66
4.03
6.77
9.6
6.4
9.25
10.43
mmol/l
0.16
22
61
26
88
3.68
6.75
9.2
7.1
7.43
7.42
ph
0.28
18
49
58
353
2.62
5.01
4.1
2.7
—
—
estimate
—
0
0
16
47
3.89
5.00
12.4
8.8
95.24
92.79
%
1.27
16
47
25
100
3.03
4.87
9.0
5.0
1.08
1.07
mmol/l
0.05
25
91
15
45
3.77
4.54
4.9
3.6
—
—
—
0
0
40
217
2.45
4.24
4.8
2.9
—
—
—
0
0
18
64
3.23
4.23
2.6
2.2
2.29
12.75
ug/l
1.59
18
56
13
32
4.53
4.09
1.6
1.3
260.05
113.77
u/ml
0.31
13
26
22
90
2.87
4.08
3.4
1.5
—
—
—
0
0
33
167
2.49
4.04
2.2
1.7
1.29
1.79
mg/l
0.45
25
133
11
23
5.26
4.01
2.6
3.3
0.17
3.57
index
—
6
14
26
120
2.60
3.83
2.5
1.9
—
—
—
0
0
17
63
3.06
3.72
1.5
2.0
0.22
0.22
g/l
0.16
17
56
16
60
3.00
3.43
1.6
2.7
—
—
—
0
0
55
370
2.14
3.27
15.8
13.1
1.22
1.24
inr
0.16
49
301
10
25
4.34
3.19
3.4
2.4
233.30
251.04
ug/l
—
10
25
6
8
7.90
3.10
1.2
1.5
—
—
—
0
0
42
259
2.11
3.10
6.8
5.2
—
—
—
0
0
33
186
2.18
3.05
2.3
1.9
2.34
2.94
mg/l
1.24
28
161
11
32
3.75
3.01
1.4
1.0
—
—
—
0
0
38
232
2.06
2.83
6.5
4.1
7.39
7.40
ph
0.35
29
164
23
115
2.32
2.80
12.7
5.6
104.52
105.17
mmol/l
0.30
23
115
19
87
2.48
2.80
1.7
1.3
337.14
498.18
titre
—
7
22
12
43
3.05
2.76
4.8
3.1
—
—
—
0
0
38
234
2.03
2.75
6.6
4.4
—
—
—
0
0
46
304
1.99
2.73
4.1
4.0
21.67
50.82
ng/l
1.33
33
217
21
107
2.23
2.44
1.5
1.2
1.27
8.30
u/ml
—
8
38
40
260
1.92
2.43
4.6
2.7
89.14
300.48
e6/l
0.38
34
199
5
8
6.52
2.40
1.6
2.4
—
—
—
0
0
10
34
3.16
2.36
7.6
4.1
36.88
37.01
°c
—
10
34
47
329
1.84
2.23
2.4
2.0
87.24
92.88
pmol/l
0.45
27
175
47
330
1.83
2.20
10.4
13.0
0.00
0.01
e9/l
0.60
40
267
39
263
1.81
2.05
4.7
2.4
—
—
—
0
0
24
138
1.99
2.04
1.5
1.5
2.13
2.90
g/l
1.04
15
91
40
276
1.77
1.93
3.4
3.7
—
—
—
0
0
7
22
3.35
1.92
1.6
1.0
—
—
—
0
0
21
120
1.96
1.81
3.8
2.6
2.14
2.36
e6/l
0.06
14
57
5
13
3.99
1.73
1.4
1.1
345.00
429.38
mg/l
—
5
13
14
70
2.17
1.69
15.9
6.1
—
—
—
0
0
33
223
1.73
1.67
4.5
2.6
0.42
0.50
e6/l
0.10
28
166
21
124
1.89
1.64
1.5
1.2
36.08
59.57
iu/ml
—
6
32
24
151
1.79
1.54
1.2
1.2
17.26
1.65
u/ml
—
5
46
86
768
2.15
1.49
30.6
14.7
30.59
26.42
mg/l
0.41
79
624
41
304
1.61
1.43
5.4
3.1
66.79
93.81
e6/l
0.29
33
217
7
29
2.52
1.42
1.4
2.5
24.16
25.63
mmol/l
—
7
29
8
35
2.40
1.30
1.0
1.1
—
—
—
0
0
5
18
2.87
1.30
1.2
1.2
7.80
6.54
u/l
—
5
13
88
808
2.07
1.28
35.7
17.3
4.02
3.98
mmol/l
0.71
88
788
8
38
2.20
1.21
4.3
2.6
0.56
0.67
%
—
8
38
21
136
1.70
1.21
1.8
1.6
856.37
1203.68
nmol/l
1.37
16
102
8
40
2.09
1.15
4.3
2.7
1.45
1.29
%
—
8
40
27
191
1.58
1.11
3.4
4.4
—
—
—
0
0
13
75
1.85
1.09
1.2
1.4
—
—
—
0
0
15
91
1.77
1.08
1.5
4.7
2.24
89.97
ug/l
—
7
73
9
46
2.05
1.07
1.0
1.3
—
—
—
0
0
10
54
1.95
1.01
1.5
1.5
0.97
1.69
g/l
—
10
46
20
135
1.61
0.99
1.9
1.8
—
—
—
0
0
42
334
1.46
0.99
4.0
2.9
6.20
6.12
ph
0.13
15
190
13
79
1.75
0.93
8.3
2.7
7.33
7.39
ph
—
6
45
30
226
1.48
0.92
5.4
6.6
—
—
—
0
0
49
406
1.42
0.91
4.2
3.5
0.00
0.00
estimate
—
7
88
10
58
1.81
0.83
4.9
3.3
5.11
5.19
kpa
—
10
58
48
402
1.39
0.81
4.1
3.5
0.00
0.00
estimate
—
6
87
0
25
0.00
0.80
0.0
1.3
—
200.73
—
0
12
49
414
1.37
0.78
4.3
3.5
0.00
0.00
estimate
—
6
81
5
23
2.24
0.77
1.4
1.3
—
—
—
0
0
9
54
1.73
0.77
1.2
1.5
—
—
—
0
0
23
171
1.45
0.75
5.4
3.3
1.02
1.02
kg/l
0.28
15
110
5
25
2.05
0.74
1.4
1.3
—
—
—
0
0
5
25
2.05
0.74
1.4
1.3
—
—
—
0
0
89
843
1.76
0.73
37.0
19.4
85.13
79.18
umol/l
0.37
89
826
86
805
1.66
0.73
36.4
17.3
139.38
139.78
mmol/l
0.71
86
787
13
85
1.61
0.73
2.3
2.4
14.75
13.61
nmol/l
0.12
13
78
5
26
1.97
0.71
1.4
1.3
—
—
—
0
0
71
642
1.41
0.71
30.7
19.6
14.01
13.72
%
1.13
71
637
18
242
0.68
0.69
3.2
3.1
0.00
0.00
estimate
—
5
73
7
44
1.64
0.66
6.9
2.5
23.90
23.67
mmol/l
—
7
44
12
79
1.59
0.66
2.2
1.5
—
—
—
0
0
86
810
1.59
0.64
23.5
14.3
—
—
—
0
0
5
30
1.70
0.62
1.2
1.1
—
—
—
0
0
0
23
0.00
0.59
0.0
1.1
—
—
—
0
0
6
38
1.62
0.55
7.2
3.6
—
—
—
0
0
6
39
1.57
0.54
4.0
4.2
1.57
1.54
%
—
6
34
37
315
1.28
0.51
2.4
2.1
—
—
—
0
0
13
93
1.46
0.51
1.4
1.3
—
—
—
0
0
15
112
1.40
0.48
1.5
1.5
—
—
—
0
0
14
104
1.41
0.46
1.5
1.3
—
—
—
0
0
31
262
1.27
0.45
3.7
3.2
229.02
47.28
mg/l
0.48
15
181
28
330
0.79
0.44
2.5
3.1
—
—
—
0
0
0
16
0.00
0.41
0.0
3.3
—
4.76
—
0
16
0
16
0.00
0.41
0.0
3.3
—
8.59
—
0
16
0
16
0.00
0.41
0.0
3.3
—
2.59
—
0
8
5
34
1.50
0.41
4.6
4.9
1.06
0.87
%
—
5
28
12
89
1.40
0.40
1.5
1.6
—
—
—
0
0
5
36
1.41
0.39
1.0
1.6
—
—
—
0
0
13
99
1.36
0.38
1.5
1.5
—
—
—
0
0
6
42
1.46
0.36
1.7
1.2
—
—
—
0
0
26
221
1.24
0.36
1.4
1.4
—
—
—
0
0
28
322
0.82
0.35
4.8
3.4
0.00
0.05
estimate
—
5
82
20
231
0.83
0.25
5.3
3.6
0.00
0.02
estimate
—
6
81
89
869
1.33
0.23
42.5
22.7
132.16
135.89
g/l
1.39
89
860
89
868
1.35
0.23
42.1
22.5
30.55
30.41
pg
0.37
89
858
89
868
1.35
0.23
42.1
22.6
91.92
91.23
fl
0.85
89
858
89
868
1.35
0.23
42.9
22.7
6.96
6.68
e9/l
0.65
89
848
89
868
1.35
0.23
43.0
22.6
4.37
4.51
e12/l
1.68
89
848
89
868
1.35
0.23
43.9
22.8
39.73
40.71
%
1.11
89
857
7
90
0.76
0.23
1.7
1.5
—
—
—
0
0
89
867
1.36
0.23
42.9
22.6
248.10
245.65
e9/l
0.14
89
850
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.8
—
—
—
0
0
0
12
0.00
0.21
0.0
2.5
—
1.32
—
0
12
6
48
1.27
0.20
5.7
5.3
25.83
24.48
mmol/l
—
6
48
30
272
1.15
0.20
4.4
3.9
55.82
7.94
mg/mmol
0.49
13
178
5
65
0.76
0.17
1.0
1.3
—
—
—
0
0
8
67
1.21
0.17
1.5
1.5
—
—
—
0
0
19
187
1.02
0.00
2.9
3.2
0.68
0.80
ug/l
0.33
12
122
0
9
0.00
-0.00
0.0
19.8
—
845.89
—
0
9
0
8
0.00
-0.00
0.0
3.6
—
3.51
—
0
8
0
7
0.00
-0.00
0.0
2.9
—
89.80
—
0
7
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.7
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
337.40
—
0
5
0
9
0.00
-0.00
0.0
30.7
—
1558.00
—
0
9
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
15.2
—
8.42
—
0
5
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint M13_CALCIOSSIMUSCLE and mortality.

Females

No data

Males

Parameter HR [95% CI] p-value
M13_CALCIOSSIMUSCLE 1.461 [1.02, 2.09] 0.037
Birth year 0.993 [0.98, 1.0] 0.108

During the follow-up period (1.1.1998 — 31.12.2019), 64 out of 217 males with M13_CALCIOSSIMUSCLE died.

Mortality risk

Mortality risk for people of age

years, who have M13_CALCIOSSIMUSCLE.

N-year risk Females Males
1 No data 0.288%
5 No data 2.012%
10 No data 5.072%
15 No data 9.751%
20 No data 16.361%

Relationships between endpoints

↥

Index endpoint: M13_CALCIOSSIMUSCLE – Calcification and ossification of muscle

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data